A Study to Determine the Activity of SCH 717454 in Subjects With Osteosarcoma or Ewing's Sarcoma That Has Relapsed After Standard Systemic Therapy
Phase of Trial: Phase II
Latest Information Update: 09 Jun 2017
At a glance
- Drugs Robatumumab (Primary)
- Indications Ewing's sarcoma; Osteosarcoma
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 10 Jun 2017 Biomarkers information updated
- 01 May 2016 This trial is completed in Netherlands, Hungary and UK (31/08/2011) along with Germany and Italy as per European Clinical Trials Database record.
- 14 Mar 2016 According to ClinicalTrials.gov record, the study was prematurely terminated for strategic reasons, not for a safety concern.